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ABSTRACT
Angiogenesis and bone formation are intimately related processes. Hypoxia during early bone development stabilizes hypoxia-inducible
factor-1a (HIF-1a) and increases angiogenic signals including vascular endothelial growth factor (VEGF). Furthermore, stabilization of HIF-
1a by genetic or chemical means stimulates bone formation. On the other hand, deficiency of Runx2, a key osteogenic transcription factor,
prevents vascular invasion of bone and VEGF expression. This study explores the possibility that HIF-1a and Runx2 interact to activate
angiogenic signals. Runx2 over-expression in mesenchymal cells increased VEGF mRNA and protein under both normoxic and hypoxic
conditions. In normoxia, Runx2 also dramatically increased HIF-1a protein. In all cases, the Runx2 response was inhibited by siRNA-
mediated suppression of HIF-1a and completely blocked by the HIF-1a inhibitor, echinomycin. Similarly, treatment of preosteoblast cells
with Runx2 siRNA reduced VEGF mRNA in normoxia or hypoxia. However, Runx2 is not essential for the HIF-1a response since VEGF is
induced by hypoxia even in Runx2-null cells. Endogenous Runx2 and HIF-1awere colocalized to the nuclei of MC3T3-E1 preosteoblast cells.
Moreover, HIF-1a and Runx2 physically interact using sites within the Runx2 RUNT domain. Chromatin immunoprecipitation also provided
evidence for colocalization of Runx2 and HIF-1a on the VEGF promoter. In addition, Runx2 stimulated HIF-1a-dependent activation of an
HRE-luciferase reporter gene without requiring a separate Runx2-binding enhancer. These studies indicate that Runx2 functions together
with HIF-1a to stimulate angiogenic gene expression in bone cells and may in part explain the known requirement for Runx2 in bone
vascularization. J. Cell. Biochem. 112: 3582–3593, 2011.  2011 Wiley Periodicals, Inc.
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B one development and regeneration require an adequateblood supply. During embryogenesis, blood vessels penetrate
into the avascular cartilage anlage, a necessary event for subsequent
bone formation. At least two important pathways are involved in
bone vascularization. The first is driven by the hypoxic environment
first present in early mesenchymal condensations destined to form
bone and uses the angiogenic transcription factor, hypoxia-
inducible factor 1a (HIF-1a), while the second requires the master
transcriptional activator of bone formation, Runx2.
HIF-1a protein levels are tightly regulated by oxygen tension via
controlled proteolysis [Salceda and Caro, 1997]. Under normoxic
conditions, prolyl residues near the C-terminus of HIF-1a are
hydroxylated by an oxygen-dependent prolyl hydroxylase that
serves as an oxygen sensor. Hydroxylated HIF-1a binds to von
Hippel-Lindau protein (VHL), a target of the E3 ubiquitin ligase
complex [Maxwell et al., 1999]. The formation of the HIF-1-VHL
complex leads to rapid degradation of HIF-1a protein by the
ubiquitin-proteosome pathway. On the other hand, in hypoxic
environments, prolyl hydroxylation of HIF-1a is blocked and the
protein becomes resistant to proteolysis [Salceda and Caro, 1997;
Huang et al., 1998]. The stabilized HIF-1-a protein accumulates
in the nucleus where it heterodimerizes with the constitutively
expressed HIFb subunit (also known as the aryl hydrocarbon
receptor nuclear translocator or ARNT). This ab-heterodimeric HIF-
1 transcription factor complex binds to hypoxia-response elements
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promotor regions of angiogenic genes such as VEGF [Forsythe et al.,
1996], erythropoietin [Firth et al., 1994] and transforming growth
factor-b3 [Schaffer et al., 2003].
HIF-1a activation, angiogenesis, and bone formation are
intimately related events. During development, initial mesenchymal
condensations destined to form limbs (first seen at E10.5 in mice)
exist in a hypoxic environment that induces HIF-1a. This early
HIF-1a expression is necessary for formation of normal cartilage
primordia and subsequent hypertrophy as well as joint development
[Provot et al., 2007]. Similarly, osteoblast-specific deletion of
HIF-1a impairs long bone formation and vascularization while
activation of HIF-1a by osteoblast-specific deletion of VHL
stimulates bone formation [Wang et al., 2007].
Like HIF-1a, Runx2 is first expressed in mesenchymal con-
densations of developing limbs and persists throughout skeletal
development [Ducy et al., 1997]. Although Runx2 is best understood
as a master regulator of skeletogenesis, it is also essential for
vascular invasion of bone primordia. In addition to completely
blocking the formation of osteoblasts and hypertrophic chondro-
cytes, Runx2 deletion prevents vascular invasion of the cartilage
anlage [Komori et al., 1997; Otto et al., 1997]. This vascularization
defect is related to decreased expression of the angiogenic cytokine,
vascular endothelial growth factor (VEGF), which can also be
induced by transfection of cells with a Runx2 expression vector
[Zelzer et al., 2001]. In addition, Runx2 is transiently expressed in
vascular endothelial cells and vascular smooth muscle cells of
developing blood vessels, which may also be related to its role in
angiogenesis [Sun et al., 2001; Bronckers et al., 2005].
The observation that both HIF-1a and Runx2 have roles in bone
formation and vascularization compelled us to examine whether
these two factors interact to regulate angiogenic signals. As will
be shown, both Runx2 and HIF-1a can induce VEGF and these
two factors complement each other for maximal VEGF induction.
Furthermore, Runx2 and HIF-1a physically interact in the nucleus
of osteoblasts and on the chromatin of the VEGF gene. This study
expands our understanding of the relationship between angiogene-
sis and bone formation, possibly providing the biological basis for
integrating osteogenesis and angiogenesis in future therapeutic
interventions to accelerate bone healing.
MATERIALS AND METHODS
CELL CULTURE
C3H10T1/2 cells, a pluripotent murine mesenchymal cell line,
and HEK293 cells, both obtained from American Tissue Culture
collection, were plated at the density of 50,000 cells/cm2 in DMEM
containing 10% FBS (Hyclone Laboratories, Logan, UT) and 1%
antibiotics. MC3T3-E1 subclone 4 and 42 cells were maintained in
a-MEM supplemented with 10% FBS and 1% antibiotics. Both cell
lines express osteoblast markers and mineralize after growth in
ascorbic acid-containing medium [Xiao et al., 1997; Wang et al.,
1999]. An mTERT (mouse telomerase reverse transcriptase)-
immortalized calvarial cell line from Runx2 null mice [Bae et al.,
2007] was a generous gift from Dr. Jane Lian (University of
Massachusetts Medical Center, Worcester, MA). These cells
were maintained in a-MEM supplemented with 5% FBS and 1%
antibiotics. Antibiotics were purchased from Invitrogen (10,000
Units/ml penicillin, 10mg/ml stereptomycin). For the induction of
hypoxia, cells were grown in an atmosphere containing 1% O2,
5% CO2, and 94% Nitrogen using an air-tight chamber (Billups-
Rothenburg, Del Mar, CA) after changing the media. Alternatively,
hypoxia mimetic conditions were induced by culturing cells in CoCl2
(100mM, Sigma), a potent inhibitor of HIF-1a degradation [Hofer
et al., 2001].
ADENOVIRAL TRANSDUCTION AND TRANSFECTION WITH SMALL
INTERFERING RNAs (siRNA)
Cells were transduced with adenovirus containing Runx2 cDNA
(AdRunx2) or LacZ(AdLacZ, control) at the indicated titer as
previously described [Yang et al., 2003]. After 48 h, cells were
cultured under normoxic/hypoxic/hypoxia mimetic conditions and
harvested at various time points. Cells were transfected with siRNA
duplexes at 50% confluency using HiPerfect (Qiagen). Specific
siRNAs for mouse HIF-1a (SI 00187915), Runx2 (SI 00193032), and
negative control siRNA (1027280) were purchased from Qiagen and
used at a concentration of 20 nM according to the manufacturer’s
instructions.
MEASUREMENT OF Runx2, HIF-1a, AND VEGF PROTEIN LEVELS
Runx2 and HIF-1a proteins were measured by Western blotting,
Briefly, cells were washed with ice cold PBS and lysed in RIPA buffer
containing complete protease inhibitor cocktail (Roche Diagnostics,
IN), 1mM DTT, 1mM PMSF. Lysates were fractionated by SDS–
PAGE on 4–12% precast minigels (Invitrogen) and transferred to
PVDF membranes. The following primary antibodies were used at a
1:500 dillution: anti-HIF-1a (NB100-105; Novus Biologicals), anti-
Runx2 (D130-3, MBL), and anti-tubulin (loading standard-Sigma).
Second antibody of sheep anti-mouse or donkey anti-rabbit-
conjugated horseradish peroxidase was used at 1:1,00,000 dillution.
Blots were visualized by ECL (Amersham).
VEGF in conditioned medium was measured by ELISA using a
Mouse VEGF Duo-Set ELISA kit (R&D systems) that recognizes 164
and 120 amino acid residue forms of the mouse protein. The amount
of secreted VEGF was normalized to the total cellular protein in
each well.
QUANTITATION OF mRNA
Real-time quantitative RT-PCR was performed as described [Zhao
et al., 2005]. Briefly, total RNA was extracted by TRIzol reagent
(Invitrogen) and further purified by DNase treatment (Ambion).
Reverse transcription was performed using Taqman reverse
transcriptase reagents (Applied Biosystems) and 2mg of total
RNA. Real-time Q-PCR was performed using an ABI Prism 7700
Sequence Detection system (PE Applied Biosystems, Foster City, CA).
TaqMan1 Universal PCR Master Mix and Optimized FAM labeled
probes and primers were purchased from Applied Biosystems
(TaqMan1 Gene Assay probes); Mouse HIF-1a (Mn00468869_m1),
Runx2 (Mn00501578_m1), VEGF (Mm00437304_m1), b-ACTIN
(Mm01205647_91), GAPDH (Mm99999915_g1). The real-time PCR
product, mRNA expression, was calculated based on a relative
standard curve and normalized to GAPDH.
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IMMUNOFLUORESCENCE LOCALIZATION OF Runx2 AND HIF-1a
Confocal microscopy was performed as described previously [Li
et al., 2010]. MC3T3-E1 clone 42 cells were grown on glass cover
slips under normoxic or hypoxic conditions. After 8 h, cells were
fixed with 4% formaldehyde and incubated overnight with primary
antibodies to Runx2 and HIF-1a (1:100 dilutions). To localize the
Runx2 and HIF-1a in the cell, the secondary antibody Alexa Fluor
555-conjugated donkey anti-rabbit (red color, Invitrogen) and
Alexa Fluor 488-conjugated donkey anti-mouse (green color,
Invitrogen) were added for 1 h. Finally, the slides were mounted
using mounting medium containing DAPI (blue color, ProLong Gold
antifade reagent; Invitrogen). Fluorescence localization was
evaluated with Olympus FluoView 500 laser scanning confocal
microscope system (Microscopy and Image Analysis Laboratory,
University of Michigan School of Medicine). The fully maximized
single image in the sequential series of Z-planes was detected by
searching for the digitally captured image with brightest fluorescent
emission.
CO-IMMUNOPRECIPITATION (IP) STUDIES
To measure the interaction of Runx2 with endogenous HIF-1a,
MC3T3-E1 Clone 42 cells were cultured in a-MEM for 48 h. The
proteosome inhibitor, MG132 (5mM), was added to the medium 12 h
before harvest. Cells were then scraped into RIPA buffer containing
protease inhibitor cocktail (Roche), centrifuged and subjected to IP
with Runx2 or HIF-1a antibodies. SDS–PAGE and Western Blotting
following standard laboratory protocols were used to visualize the
results. To determine the Runx2 domain responsible for the HIF-1a
interaction, various C and N-terminal deletion constructs were
generated by subcloning the desired PCR products into appropriate
expression vectors (below) followed by verification using DNA
sequencing. Wildtype Runx2 and Runx2 with C-terminal deletions
after amino acids 410, 330, 286, or 258 (410dC, 330dC, 286dC,
258dC) were subcloned into the pCMV5-FLAG vector [Thiruna-
vukkarasu et al., 1998]. Wildtype Runx2 WT and Runx2 with N-
terminal deletions to amino acid 97, 232, 242, 376 (dN97, 232, 242,
376) were subcloned into the pPGS-NEO-CITE-HA carrier DNA
vector. Expression constructs were transfected into HEK293 cells
together with HIF-1a expression vector using lipofectamine
(Invitrogen). For each sample, 20ml of Protein A/G plus (Santa
Cruz) beads and 0.5–1mg of each indicated antibody were used for
IP. Finally, the beads were boiled in 60ml of 1 SDS sample buffer
and 20ml of each sample was used for SDS–PAGE analysis. Western
Blotting was performed after the samples were transferred to PVDF
membranes. Studies used the following antibodies: HIF-1a (NB100-
105; Novus Biologicals), Runx2 (D130-3, MBL), a-tubulin (Sigma),
HA (MMS-101P Covance), and FLAG (anti-M2-HRP; Sigma).
CHROMATIN IMMUNOPRECIPITATION
ChIP assays were performed as previously described [Roca et al.,
2005; Roca and Franceschi, 2008; Li et al., 2010]. MC3T3-E1 clone 4
cells were cultured for 48 h and exposed to normoxic or hypoxic
conditions for an additional 8 h. Cells were then fixed with 1% p-
formaldehyde for 10min at room temperature to make protein–DNA
complexes. Chromatin was mechanically sheared by sonication to
yield fragmentswith a mean size of 300 bp. Before immunoprecipi-
tation, chromatin (10mg DNA/assay) was pretreated with protein
A/G agarose beads (Santa-Cruz Biotechnology) for 1 h. For the
immunoprecipitation, the supernatants were incubated with
primary antibody (Runx2, HIF-1a, and IgG) and A/G agarose beads
were used to precipitate the fragments. The input DNA and the DNA
from ChIP samples was used for PCR analysis (35 cycles). Putative
Runx2 and HIF-1a (hypoxia response element, HRE)-binding sites
in the VEGF-A promoter were analyzed using following primer sets
(position on promoter is indicated): Runx2 site 50 primer (Primer
1¼334 to315), 50-GCCTTCCAACCCCTACTTTC-30; Runx2 site 30
primer (Primer 2¼201 to182), 50-ATCTGTGCACCCCTTCAAAC-
30; HRE 50 primer (Primer 3¼952 to 971), 50-CCCAGCTGT-
CTCTCCTTCAG-30; HRE 30 primer (Primer 4¼717 to 698),
50-ATATGTGGGGAGGGGGTTAC-30. Primers were also designed to
detect the presence of DNA within the VEGF transcribed region,
which served as a control for off-target immunoprecipitation
(Primer 5¼þ285–304, 50-TGTGGAAATCAGCAGACGAA-30; Primer
6¼þ491–510, 50-GCGGTGTCTGTCTGTCTGTC-30).
LUCIFERASE ASSAY
For the reporter gene assays, C3H10T1/2 cells were transiently
transfected with a HRE (hypoxia responsive element)-Luc reporter
plasmid composed of pGL2 vector with 68 bp of Enolase 1 promoter
sequence containing 2 HRE sites [Semenza et al., 1996]. Cells were
plated in six-well plates a density of 5 104 cell/cm2, grown for
12 h, and transfected with 250 ng of HRE-luciferase reporter
construct (pGL2-HRE) plus 250 ng of pGL4-SV40 Renilla luciferase
vector (Promega) for normalization. Five-hundred nanogram of
RUNX2 expression vector (pCMV5-Runx2), control (pCMV5-LacZ)
vector, or HIF-1a (pCEP-HIF-1a) expression plasmid were utilized.
Luciferase activity was measured with the reagents and protocols
from Promega and were subjected to normoxic/hypoxic conditions
for 24 h.
STATISTICAL ANALYSIS
Results are presented as mean SE, with n¼ 3 per group for all
comparisons. Statistical significance was assessed using a one-way
ANOVA followed by Tukey’s multiple-comparison test. All experi-
ments were repeated at least twice.
RESULTS
Runx2 OVER-EXPRESSION INCREASES VEGF AND HIF-1a
Developmental studies suggest a possible functional interaction
between Runx2 and HIF-1a in regulating angiogenesis. To
determine whether increased Runx2 can stimulate angiogenetic
signaling, pluripotent C3H10T1/2 mesenchymal cells, which do not
express detectable Runx2, were transduced with a Runx2-expres-
sing adenovirus (AdRunx2) and assayed for VEGF and HIF-1a
protein and mRNA after exposure to normoxic, hypoxic, or hypoxia
mimetic conditions (CoCl2 treatment). Consistent with previous
reports [Zelzer et al., 2001], Runx2 dose-dependently increased
VEGF protein (Fig. 1A,B) and mRNA levels (Fig. 1G). The Runx2
response was most dramatic in the normoxic condition where,
depending on the experiment, 2.8- to 8-fold increases in VEGF
secretion were observed (compare normoxic condition in Fig. 1A,B).
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The magnitude of Runx2 stimulation was comparable to that seen
with hypoxia or hypoxia-mimetic conditions. Runx2 also increased
VEGF in hypoxia and in the presence of CoCl2, although the fold
stimulation was somewhat less, possibly because of the elevated
VEGF levels seen under these conditions. In addition, Runx2
increased the normally low levels of HIF-1a protein seen in
normoxia, but did not affect the elevated levels of HIF-1a seen in the
hypoxic condition (Fig. 1C,D). This response appears to be at the
protein level in that Runx2 did not affect HIF-1a mRNA (Fig. 1E).
Taken together, these studies show that Runx2 overexpression can
induce VEGF mRNA and protein and that this effect is additive with
hypoxia in stimulating this angiogenic signal.
DEPLETION OF ENDOGENOUS Runx2 USING BOTH siRNA
AND GENETIC APPROACHES INHIBITS VEGF EXPRESSION IN
OSTEOBLASTS, BUT DOES NOT PREVENT THE RESPONSE
TO HYPOXIA
Because the studies in Figure 1 used overexpression to demonstrate
a role for Runx2 in VEGF synthesis, we considered it important to
also determine whether endogenous Runx2 is required for VEGF
expression. Two approaches were taken. In the first, siRNA was used
to suppress Runx2 in MC3T3-E1 preosteoblast cells. These cells
normally express Runx2 at high levels and differentiate into
osteoblasts after growth in osteogenic medium [Wang et al., 1999].
Runx2 siRNA selectively reduced Runx2 protein and mRNA levels
by 50–65% in both normoxic and hypoxic conditions without
affecting either HIF-1a mRNA or a-tubulin (Fig. 2A,B). Although
these cells do not express enough VEGF to be readily detected by
ELISA (result not shown), exposure to hypoxia induced VEGFmRNA
approximately sevenfold (Fig. 2C). Treatment with Runx2 siRNA
reduced VEGF mRNA by approximately 30% in the normoxic
condition and by 40% in hypoxia. However, cells were still able to
respond to the hypoxic stimulus, albeit at a reduced level (i.e.,
hypoxia stimulated VEGF mRNA sevenfold in control cells and this
induction was reduced to only sixfold with Runx2 siRNA treatment).
Since the siRNA approach only partially reduced Runx2 levels, a
second strategy was used to determine whether hypoxia can induce
VEGF in the complete absence of Runx2. For this study, we used a
Fig. 1. Runx2 regulation of VEGF and HIF-1a. C3H10T1/2 cells were transduced with AdRunx2 at the indicated multiplicity of infection (MOI), grown for 48 h and cultured
for 18 h under normoxic/hypoxic conditions or in the presence or absence of 100mM CoCl2. VEGF in conditioned medium was analyzed by ELISA (A,B) while HIF-1a, Runx2 and
a-tubulin levels were determined by Western blotting (C,D). For mRNA analysis (E–G), cells were transduced at an moi of 10 using control AdLacZ virus () or AdRunx2 (þ) and
transferred to normoxic/hypoxic conditions for 8 h before measurement of HIF-1a (E), Runx2 (F) and VEGF (G) mRNAs by QRT-PCR. Values are means SD of triplicate
independent samples. Statistics: a, significantly different from normoxic LacZ control; b, significantly different from hypoxic LacZ control; c, significantly different from
corresponding normoxic sample (same AdRunx2 titer). For all comparisons, P< 0.05.
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calvarial cell line derived from Runx2-null mice. These cells fail
to undergo osteoblast differentiation unless Runx2 is restored by
transfection [Bae et al., 2007]. Exposure of Runx2-null cells to
hypoxia increased VEGF protein approximately fourfold (Fig. 2D).
Similar to results obtained with C3H10T1/2 cells in Figure 1,
AdRunx2 caused a threefold increase in VEGF in the normoxic
condition and a 2.5-fold increase in hypoxia. These results show that
Runx2 can increase VEGF expression in normoxic and hypoxic
conditions, but this factor is not essential for the basal HIF-1a-
mediated response of cells to hypoxia.
DEPENDENCE OF THE Runx2 RESPONSE ON HIF-1a AND EFFECTS
OF Runx2 ON HIF-1a-DEPENDENT TRANSCRIPTIONAL ACTIVITY
The next series of studies examined whether Runx2 induction
of VEGF requires HIF-1a. Both siRNA (Fig. 3A,B) and chemical
inhibition approaches (Fig. 3C) were used to address this issue.
Treatment of C3H10T1/2 cells with a specific siRNA reduced HIF-1a
mRNA by 70% in both normoxic and hypoxic conditions (Fig. 3A).
Densitometric analysis of Western blots also indicated substantial
reduction in HIF-1a protein. In normoxia, siRNA treatment reduced
the already low HIF-1a protein to below the level of detection.
However, substantial amounts of HIF-1a protein were still present in
the hypoxic condition, probably as a consequence of stabilization in
the low oxygen environment. Under this condition, HIF-1a siRNA
reduced protein levels by about 50%. Effects of HIF-1a suppression
were also apparent when VEGF protein levels were examined
(Fig. 3B). In both normoxic and hypoxic conditions, HIF-1a siRNA
blocked the Runx2-dependent induction of VEGF by approximately
50%. To gain further insight into the role of HIF-1a in the Runx2
response, we also blocked HIF-1a signaling with the specific
Fig. 2. Runx2 is necessary for maximal VEGF expression. A–C: Runx2 siRNA inhibits hypoxic induction of VEGF mRNA. MC3T3-E1 clone 4 cells were treated with 20 nM Runx2
siRNA (þ) or control siRNA () for 36 h and cultured for an additional 8 h in normoxic or hypoxic conditions. RNA and protein were then isolated for measurement of Runx2 (A),
HIF-1a (B), and VEGF mRNAs (C) by QRT-PCR or Runx2 protein (A, lower panel). D: Response of Runx2-null cells to hypoxia. An mTert-immortalized calvarial cell line from
Runx2 (/) mice was exposed to control or hypoxic conditions with (þ) or without () transduction with AdRunx2 (MOI¼ 10) before measurement of medium VEGF by
ELISA. Conditions were as in Fig. 1A–D). Statistics: panels A–C: a, significantly different from siRNA control. Panel D: a, significantly different from corresponding LacZ control;
b, significantly different from corresponding normoxic sample. For all comparisons, P< 0.05.
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inhibitor, echinomycin. This compound selectively inhibits the
ability of HIF-1a to interact with hypoxia response elements (HREs)
in the regulatory regions of target genes [Kong et al., 2005]. As
shown in Figure 3C, echinomycin completely blocked hypoxia and
Runx2-dependent induction of VEGF without affecting Runx2
levels.
Figure 3D shows that Runx2 can also stimulate HIF-1a-
dependent activation of an HRE-luc reporter gene [Semenza
et al., 1996] in cells exposed to hypoxia. Since this reporter can
only directly respond to HIF-1a (e.g., it does not contain Runx2 or
other transcription factor-binding sites), this stimulation is most
likely related to Runx2-binding/stabilization of HIF-1a. In contrast,
a Runx2 reporter gene, 6OSE2-luc [Ducy et al., 1997], was clearly
stimulated by Runx2 in normoxic and hypoxic conditions, but
hypoxia and HIF-1a stabilization did not further activate this
reporter.Consistent with echinomycin having selective effects on
HIF-1a-dependent transcription, it totally blocked hypoxia and
Runx2-dependent induction of HRE-luc without affecting Runx2-
specific induction of 6OSE2-luc.
These results taken together with the siRNA studies suggest
that actions of Runx2 on VEGF expression may be dependent
on HIF-1a. In contrast, HIF-1a can function in the absence of
Runx2 although its activity is increased by this transcription
factor.
NUCLEAR COLOCALIZATION AND PHYSICAL INTERACTION
BETWEEN Runx2 AND HIF-1a; IMPORTANCE OF THE
RUNT DOMAIN
To begin exploring the mechanism accounting for the functional
interactions between Runx2 andHIF-1a demonstrated in Figures 1–3,
we looked for a possible physical association between these two
proteins. An initial study examined the subcellular localization of
Runx2 and HIF-1a in MC3T3-E1 cells using confocal immunofluo-
rescence microscopy (Fig. 4A). As previously reported [Javed et al.,
Fig. 3. Runx2 induction of VEGF requires HIF-1a. A,B: siRNA suppression of HIF-1a inhibits VEGF secretion. C3H10T1/2 cells were transfected with control () or HIF-1a
siRNA (þ). Twenty-four hours later, cells were transduced with AdRunx2 or AdLacZ control virus and grown in normoxic/hypoxic conditions for an additional 24 h. Cells and
medium were then harvested for measurement of HIF-1a mRNA and protein (A) and medium VEGF (B). C: The specific HIF-1a inhibitor, echinomycin, blocks hypoxia-induced
VEGF secretion. Cells were transduced with AdlacZ or AdRunx2 (MOI¼ 20) and grown in normoxic or hypoxic conditions for 24 h with or without echinomycin (20 nM)
as indicated. Cell layers and medium were harvested for measurement of Runx2 and VEGF, respectively. D,E: Specificity of echinomycin inhibition and effects of Runx2 on
HRE-dependent transcriptional activity. Cells were transfected with either a 6HRE-luc reporter (D) or with a 6OSE2-luc reporter (E) and grown with or without Runx2 for 24 h
under normoxic or hypoxic conditions with or without echinomycin treatment before measurement of luciferase as described in Materials and Methods section. Statistical
analysis: a, P< 0.05.
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2005], Runx2 exhibited an exclusively nuclear distribution in both
normoxic and hypoxic conditions (red channel). Although
normoxic cells displayed weak HIF-1a fluorescence due to the
known instability of this protein under this condition [Hirota and
Semenza, 2006], the signal detected was mainly in the nucleus.
Exposure of cells to hypoxia dramatically increased the overall HIF-
1a signal with most of the protein again appearing in the nucleus.
Interestingly, merging of the two signals indicated considerable
colocalization of HIF-1a and Runx2 in the nuclear compartment
(yellow color) in both normoxia and hypoxia.
A series of co-immunoprecipitation (Co-IP) experiments were
next carried out to further explore the basis for the Runx2-HIF-1a
interaction. The first series of studies examined interactions between
endogenous Runx2 and HIF-1a in MC3T3-E1 cells. Nuclear extracts
were immunoprecipitated with either Runx2 or HIFa antibodies
and the resulting precipitates were probed for Runx2 or HIF-1a
on Western blots (Fig. 4B). These results indicate that Runx2 and
HIF-1a form a protein complex in osteoblasts.
To identify the domain structures in Runx2 that are responsible
for the interaction with HIF-1a, Flag-tagged C-terminal or HA-
tagged N-terminal deletion constructs of Runx2 were generated and
transfected into HEK293 cells together with a HIF-1a expression
vector (Fig. 5). Positions of deletions relative to the domain structure
of Runx2 are shown in Figure 5A,C. All C-terminal Runx2 deletions
available down to amino acid residue 258 could be immunopre-
cipitated with HIF-1a (Fig. 5B). These deletions spanned a C-
terminal repression domain and the proline/serine/threonine-rich
activation domain. Analysis of N-terminal deletions indicated
retention of binding if the first 97 N-terminal amino acid residues
containing the glutamine/alanine-rich domain were deleted, but
loss of binding with all further deletions starting with loss of the
RUNT domain (Fig. 5D). Cell lysates were also analyzed by Western
Blotting to verify comparable Runx2 expression levels in different
samples. Since all C-terminal deletions up to the C-terminal
boundary of the RUNT domain retained binding to HIF-1awhile the
RUNT domain N-terminal deletion lost this binding, we conclude
Fig. 4. Colocalization and physical association of Runx2 and HIF-1a. A: Co-localization of HIF-1a and Runx2. MC3T3-E1 clone 42 cells were grown on glass coverslips and
exposed to normoxic or hypoxic conditions for 8 h, fixed and stained as described in Materials and Methods section. Legend: HIF-1a (green), Runx2 (red), and DAPI (blue) for
nuclear staining. Fluorescence localization was evaluated using laser scanning confocal microscopy. B: Co-immunoprecipitation. Cells were grown for 48 h and MG132 was
added to medium 12 h before harvesting. Cell lysates were immunoprecipitated with Runx2, HIF-1a antibody or IgG (control) followed by immunoblotting of Runx2 or HIF-1a
antibody as indicated.
3588 Runx2 REGULATION OF HIF-1a ACTIVITY JOURNAL OF CELLULAR BIOCHEMISTRY
that the HIF-1a interacting domain is within the RUNT domain of
Runx2.
Runx2 AND HIF-1A INTERACT ON SPECIFIC SITES IN
VEGF PROMOTER
Figure 6A shows a schematic of the proximal murine Vegf-A
promoter with the positions of consensus HIF-1a and Runx2-
binding sites indicated. Shown are a previously characterized
functional HRE at -926 bp from the transcription start site [Forsythe
et al., 1996; Oosthuyse et al., 2001] and several putative Runx2-
binding sites at 855, 606, and 266 bp [Peng et al., 2006].
Chromatin immunoprecipitation (ChIP) was used to examine Runx2
and HIF-1a interactions with this gene region in intact MC3T3-E1
cells. PCR primers were designed to detect immunoprecipitation of
chromatin containing the 50 HRE and adjoining Runx2 sites (site 1),
the 30 Runx2 site (site 2) as well as a control region in the transcribed
portion of the Vegf-A gene that is free of either binding site (site 3).
ChIP analysis with the site 1 and site 2 primer pairs detected positive
signals with both Runx2 and HIF-1a antibodies while no signal was
detected with isotype-matched IgG or with the control site 3 primers.
As would be expected if HIF-1awere binding to the HRE at926 bp,
the site 1 primer pair detected a strong signal with HIF-1a antibody
and this signal increased with hypoxia. In addition, a weaker, but
still specific, signal was detected with the Runx2 antibody. Since the
two 5’ consensus Runx2 sites are within 100 bp of the site 1
amplified region, it is not possible to discriminate between binding
of Runx2 directly to DNA or to HIF-1a bound to its HRE. The site 2
primer pair detected a strong signal with Runx2 antibody that was
not affected by oxygen status. This likely reflects binding of Runx2
to the site at 266 bp. Interestingly, a weaker signal was also
detected with the HIF-1a antibody using this primer pair that was
mildly increased by hypoxia. In this case, it is likely that HIF-1a
associates with this chromatin region via interactions with Runx2 or
some other protein rather than with an HRE. The nearest HRE at
926 bp is nearly 750 bp distant from the 30 site 2 primer pair, too
far away to be in the same amplified chromatin fragment as the
Runx2-binding site at266 bp. The observation that no Runx2 ChIP
signal was detected with the site 3 primers is consistent with this
interpretation since these primers amplify a DNA region that is only
470 bp away from the Runx2 site, yet failed to detect a Runx2 signal.
These studies show that both HIF-1a and Runx2 are associated with
the Vegf-A promoter in intact cells and provide evidence for both
direct binding of each factor to its respective enhancer sequence on
DNA as well as possible indirect binding of HIF-1a to Runx2-
binding regions via protein–protein interactions.
DISCUSSION
This study explores the relationship between HIF-1a and Runx2 in
the control of VEGF gene expression and shows how canonical
Fig. 5. Identification of the HIF-1a interacting region of Runx2. The indicated FLAG-tagged C-terminal (panels A,B) and N-terminal (panels C,D) deletion mutants of Runx2
were constructed and transfected into HEK293 cells with wild type HIF-1a as described in Materials andMethods section. Nuclear extracts were immunoprecipitated with anti-
HIF-1a antibody and blots probed with HIF-1a or anti-FLAG antibody as indicated. Runx2 domain structure: QA, glutamine/alanine-rich domain; RUNT, runt homology domain;
NLS, nuclear localization signal; TAD, transactivation domains; RD, repression domain.
JOURNAL OF CELLULAR BIOCHEMISTRY Runx2 REGULATION OF HIF-1a ACTIVITY 3589
angiogenic and osteogenic transcription factors can function
together to regulate an angiogenic signal. In contrast to studies
that examined separate roles of HIF-1a and Runx2 in angiogenesis,
the present work examined interactions between these two factors
and found that HIF-1a and Runx2 physically and functionally
interact to control VEGF synthesis. Although HIF-1a was able to
respond to hypoxic stimuli in Runx2 null cells, the magnitude of
VEGF induction in hypoxia was enhanced in the presence of Runx2.
Of further interest, Runx2 strongly induced VEGF mRNA and
protein expression even in normoxic conditions where HIF-1a
protein levels are characteristically very low. Nevertheless, this
induction required HIF-1a in that it could be strongly inhibited by
HIF-1a siRNA or the HIF-1a inhibitor, echinomycin. Runx2 and
HIF-1a were colocalized to discrete nuclear regions in target cells
and shown to physically interact through sites in the Runx2 runt
domain. ChIP analysis provided further evidence that Runx2 and
HIF-1a interact on the chromatin of the Vegf-A gene.
The impetus for our work came from a number of previous studies
suggesting a possible relationship between Runx2 and HIF-1a in
angiogenesis and bone formation. To begin with, Runx2 and HIF-1a
have similar patterns of expression during early skeletal develop-
ment. In mice, mesenchymal condensations destined to form bone
stain positive for HIF-1a beginning at E10.5. These regions are also
hypoxic and exhibit HIF-1a-dependent transcriptional activity as
detected by activation of an HRE-LacZ transgene [Provot et al.,
2007]. Runx2 shares a similar time course and pattern of expression
with HIF-1a, being localized to mesenchymal condensations as
early as E9.5 [Ducy et al., 1997; Kim et al., 1999]. Furthermore, both
HIF-1a and Runx2 have clearly established roles in skeletal
development and vascularization. Early conditional deletion of HIF-
1a in limb bud mesenchyme using a Prx1-Cre resulted in major
cartilage anomalies including defects in growth plate formation,
delayed hypertrophy leading to limb shortening and joint
abnormalities [Provot et al., 2007]. More selective, later deletion
of HIF-1a in chondrocytes using a col II-Cre led to impaired
chondrocyte survival in hypoxic areas and reduced VEGF
expression [Schipani et al., 2001]. In addition, deletion of HIF-1a
in osteoblasts resulted in reduced long bone cortical thickness and
vascularity while activation of HIF-1a via osteoblast-specific
deletion of VHL increased VEGF expression, bone formation and
vascularity [Wang et al., 2007]. Similarly, Runx2 deletion was
associated with defective VEGF synthesis and blockade of cartilage
vascular invasion [Otto et al., 1997; Kim et al., 1999; Zelzer et al.,
2001]. This vascularization defect reflects an intrinsic property
of the bone rudiment rather than a defect in the surrounding
vasculature since transplantation of Runx2/ bones into a wild-
type host is unable to restore vascular invasion [Himeno et al., 2002].
In a related study, the human disorder, cleidocranial dysplasia,
Fig. 6. Interaction of Runx2 and HIF-1a with VEGF chromatin. A: Structure of the proximal VEGF-A promoter region showing location of putative Runx2 and
HIF-1a-binding sites and associated PCR primer pairs. Site 1, putative Runx2-binding element; site 2, HIF-1a-binding element; control site, region in the transcribed
region of Vegf. B: Chromatin immunoprecipitation. Chromatin was immunoprecipitated with the indicated antibodies and ChIP DNA analyzed with the site-specific PCR
primers indicated.
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which is caused by Runx2 haploinsufficiency, was accompanied
by diminished cartilage hypertrophy and a fivefold decrease in
VEGF expression [Zheng et al., 2005]. Lastly, a recent study
showed that Runx2 and HIF-1a interact during trauma-induced
heterotopic ossification [Lin et al., 2011]. Specifically, combined
lentiviral siRNA suppression of HIF-1a and Runx2 inhibited
bone formation to a greater degree than the knockdown of either
factor.
Of particular interest, in the present study Runx2 stimulation of
VEGF expression was observed in normoxic as well as hypoxic
conditions and appeared to be dependent on HIF-1a (Figs. 1–3).
Effects on VEGF protein were likely due to increased Vegf-a
transcription in that VEGF mRNA and protein levels generally
increased in parallel. However, Runx2 stimulation of VEGF
expression was not accompanied by a corresponding increase in
HIF-1a mRNA. Instead, Runx2 preferentially increased HIF-1a
protein levels, raising them from the low levels normally seen in
high oxygen tension where HIF-1a is highly unstable due to
oxygen-dependent hydroxylation and degradation. Possible expla-
nations for this result are that Runx2 protects HIF-1a from
proteosome-mediated degradation, increases HIF-1a translation or
inhibits hydroxylation or VHL binding. Further studies will be
required to discriminate between these possibilities. It should be
pointed out that functions of HIF-1a in normoxia are not unique to
our experimental system. A number of stimuli can activate HIF-1a
in the presence of oxygen. These include IGF-1-dependent induction
of HIF-1a and VEGF expression in human colon cancer cells
[Fukuda et al., 2002], oncogenic ras up-regulation of HIF-1a and
VEGF in tumor cells [Sodhi et al., 2001] and estrogen activation of
HIF-1a and VEGF in the uterus [Kazi and Koos, 2007].
In addition to increasing HIF-1a protein levels, Runx2 can also
increase HIF-1a-dependent transcriptional activity. This is particu-
larly apparent in the hypoxic condition where Runx2 increased
VEGF mRNA and protein without increasing HIF-1a levels. This
stimulation is likely explained by interactions between HIF-1a and
Runx2 on Vegf chromatin. ChIP analysis revealed that both factors
bind themurineVegf gene in intact cells. Strong HIF-1a binding was
detected in the region of a well-characterized HRE at 926 bp. This
site was previously shown to be essential for VEGF induction by
HIF-1a in cell culture and in vivo [Forsythe et al., 1996; Oosthuyse
et al., 2001]. Weaker Runx2 binding was also seen in this region
either due to interactions with consensus Runx-binding sites or via
protein–protein interactions with HIF-1a. Stronger Runx2 binding
was also detected in a more downstream portion of the promoter
centered around a consensus Runx site at 266. Although the
binding of Runx2 to this site has not previously been examined, the
related Runt domain factor, Runx3, can bind similar sites in the
human Vegf promoter. However, in this case, the effect of Runx3
was to inhibit VEGF expression [Peng et al., 2006]. Interestingly, this
region also bound HIF-1a even though it does not contain any HRE
consensus sites. Since the 926 bp HRE is too far away to be in this
chromatin fragment, this result is likely explained by binding of
HIF-1a to Runx2 or another as yet undefined protein in this region.
These studies suggest that Runx2 can increase HIF-1a transcrip-
tional activity via the formation of protein–protein interactions on
chromatin.
The relative importance of Runx2 and HIF-1a to Vegf expression
was assessed using a combination of siRNA knock down, genetic
and chemical inhibition experiments (Figs. 2 and 3). The overall
conclusion of these studies was that Runx2 requires HIF-1a for
activity while HIF-1a has basal activity in the absence of Runx2.
This HIF-1a activity was apparent in the experiment with Runx2-
null cells that retained a robust response to hypoxia. Nevertheless,
Runx2 augmented HIF-1a activity in MC3T3-E1 cells since siRNA
knock-down of Runx2 clearly reduced VEGF expression in
normoxic and hypoxic conditions. Partial siRNA knockdown of
HIF-1a also inhibited Runx2-dependent VEGF protein induction in
both normoxic and hypoxic conditions. To more completely block
HIF-1a activity, the chemical inhibitor, echinomycin, was used. This
compound completely blocked both HIF-1a and Runx2-dependent
induction of VEGF. Although echinomycin is reported to have off-
target effects including the ability to interfere with myc and AP-1
transcription factors [Vlaminck et al., 2007], we do not think this
explains our results. Specifically, the HRE-luc reporter used in the
experiment shown in Figure 3 is only activated by HIF-1a and does
not contain binding sites for other transcription factors. Neverthe-
less, echinomycin completely blocked HIF-1a and Runx2-depen-
dent induction of this reporter without affecting Runx2 induction of
6OSE2-luc. However, it is still possible that echinomycin interferes
with other factors on the promoter to block Runx2 and HIF-1a
induction of this gene. Further studies with HIF-1a-null cells will be
required to definitively resolve whether Runx2 requires HIF-1a for
its activity.
In further support of the concept that Runx2 and HIF-1a function
together to regulate Vegf, we observed that these two factors could
be colocalized to the nuclear compartment of MC3T3-E1 preosteo-
blast cells in both normoxic and hypoxic conditions. Furthermore,
co-immunoprecipitation studies with C and N-terminal Runx2
deletion constructs revealed that Runx2 and HIF-1a physically
interact using sequences in the runt domain of Runx2. This result is
similar to a previous report with the related runt-domain family
member, Runx1, which also interacts with HIF-1a through its runt
domain [Peng et al., 2008]. Since there is 95% amino acid sequence
conservation between the runt domains of Runx1 and Runx2, it is
likely that a conserved sequence accounts for this interaction in
both molecules. However, Runx1 inhibited the HIF-1a-dependent
activation of the HRE-luciferase reporter while, in our studies,
Runx2 stimulated this activity.
Although this study emphasized interactions between HIF-1a and
Runx2 in bone and mesenchymal cell lines, our observations may
also be relevant to other cell types such as vascular endothelial cells
that express both these factors. Although not widely appreciated,
Runx2 has clearly defined roles in normal and pathological vascular
cell biology. Runx1 and Runx2 are both present in endothelial cells
and vascular smooth muscle cells at sites of in vivo angiogenesis
[Namba et al., 2000; Bronckers et al., 2005]. Furthermore, dominant-
negative inhibition of Runx1 and 2 in murine and human
endothelial cell lines inhibited proliferation, migration and tube
formation [Namba et al., 2000; Qiao et al., 2004; Qiao et al., 2006]. It
has also been proposed that the pericyte, a vascular smooth muscle-
associated cell, can function as a mesenchymal stem cell/
osteoprogenitor competent to differentiate into an osteogenic cell
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after Runx2 induction or activation (reviewed in [Towler, 2007]).
Furthermore, pathologic vascular calcification is associated with
up-regulation of Runx2 and bone marker genes [Byon et al., 2008].
Similarly, vascular endothelial cells are one of the classic HIF-1a
targets that respond to hypoxia by expressing angiogenic factors
including VEGF and by undergoing angiogenic processes including
tubule/microvessel formation and extracellular matrix invasion
[Manalo et al., 2005]. It is, therefore, highly likely that the Runx2-
HIF-1a interaction we describe can also take place in these cells. Of
further interest, HIF-1a and hypoxia have documented roles in the
formation of atherosclerotic plaques that ultimately calcify through
a process very similar to normal bone formation [Sluimer and
Daemen, 2009].
In summary, we have shown that there is a physical and
functional interaction between the major osteogenic factor, Runx2,
and angiogenic master regulator, HIF-1a. This interaction stimu-
lates VEGF gene expression in mesenchymal osteogenic cells by
direct and indirect binding of these two factors to regulatory regions
of the Vegf gene. These studies provide a mechanism for further
clarifying the roles of Runx2 in angiogenesis and osteogenesis.
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